학술논문
SRF617, a potent enzymatic inhibitor of CD39, demonstrates single-agent activity and cooperates with various cancer therapies in both solid tumor and hematologic malignancies
Document Type
Journal
Author
Source
Subject
Language
English
ISSN
15387445